Vidofludimus

Drug Profile

Vidofludimus

Alternative Names: 4SC-101; SC-12267

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator 4SC
  • Developer 4SC; University of Munich
  • Class Amides; Anti-inflammatories; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Disease-modifying antirheumatics; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Interferon gamma inhibitors; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Inflammatory bowel diseases; Rheumatoid arthritis

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 20 Oct 2016 Discontinued - Phase-II for Inflammatory bowel disease in Germany, Bulgaria, Romania (PO) (4SC pipeline; October 2016)
  • 20 Oct 2016 Discontinued - Phase-II for Rheumatoid arthritis (Combination therapy, Monotherapy) in Bulgaria, Czech Republic, Romania, Poland (PO) (4SC pipeline; October 2016)
  • 20 Oct 2016 Discontinued - Phase-II for Rheumatoid arthritis in Germany (PO) (4SC pipeline; October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top